论文部分内容阅读
脂质紊乱是2型糖尿病病人心血管病的重要危险因素。内皮细胞功能紊乱可出现在糖尿病早期,是动脉粥样硬化和心血管疾病的早期标志,在临床实验中,其为心血管病的终点标志。Atovastatin(HMG-CoA还原酶抑制剂)可改善非糖尿病病人的脂质紊乱和内皮细胞功能,但对糖尿病病人内皮细胞功能紊乱的影响尚不清。本文旨在观察Atorvastatinq10mg(A10)和80mg(A80)对糖尿病病人内皮细胞功能的影响。对象与方法采用随机、双盲和安慰剂对照方法,将研究来自于多中心的217名糖尿病病人分为3组(A10、A80、对照组),观察脂代谢、内皮细胞功能、凝血情况和炎性因子水
Lipid disorder is an important risk factor for cardiovascular disease in type 2 diabetic patients. Endothelial dysfunction, which occurs early in diabetes and is an early marker of atherosclerosis and cardiovascular disease, is the culmination of cardiovascular disease in clinical trials. Atovastatin (HMG-CoA reductase inhibitor) can improve lipid disorders and endothelial cell function in nondiabetic patients, but its effect on dysfunction of endothelial cells in diabetic patients is unclear. This article aims to observe the effects of Atorvastatinq 10mg (A10) and 80mg (A80) on endothelial cell function in diabetic patients. Subjects and Methods A randomized, double-blind, and placebo-controlled trial of 217 diabetic patients from multiple centers was divided into 3 groups (A10, A80, control group) and lipid metabolism, endothelial cell function, coagulation, and inflammation Sexual factor water